DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (NYSE Amex: AXK) today announced that it completed the sale of a non-exclusive license for its proprietary OptiChem® bio-coatings to an innovative, public diagnostics company. The licensee is paying $1,865,000 over four annual escalating payments and intends to use OptiChem® in its disposable diagnostic devices.
According to David Howson, Accelr8’s president, “We are very pleased to have a diagnostics innovator select OptiChem after comparing a number of competing coatings. Once again, OptiChem offered superior technical attributes that improve total system performance at advantageous costs with scalable manufacturing.”
“The licensee’s products do not compete with our BACcel™ rapid diagnostic system, but complement it in different applications. This license expands our corporate presence in the clinical diagnostic segment. It also opens future licensing opportunities for additional, complementary new diagnostic applications that take advantage of the optimization we’ve achieved with OptiChem’s development,” he concluded.
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel™ system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8’s own products.
Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company’s filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.
